Updates are available Correction dated 2023-08-18
Click to view Correction: https://doi.org/10.1038/s41586-023-06543-1
-
Authors
Gourisankar, Sai
Krokhotin, Andrey
Ji, Wenzhi
Liu, Xiaofan
Chang, Chiung-Ying
Kim, Samuel H.
Li, Zhengnian
Wenderski, Wendy
Simanauskaite, Juste M.
Yang, Haopeng
Vogel, Hannes
Zhang, Tinghu
Green, Michael R. http://orcid.org/0000-0001-6309-9472
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Crabtree, Gerald R. http://orcid.org/0000-0001-9685-7911
- License Information
-
More Information
Article History
Received: 15 August 2022
Accepted: 20 June 2023
First Online: 26 July 2023
Change Date: 18 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-023-06543-1
Competing interests
: G.R.C. is a founder and scientific advisor for Foghorn Therapeutics and Shenandoah Therapeutics. N.S.G. is a founder, science advisory board member (SAB) and equity holder in Syros, C4, Allorion, Lighthorse, Voronoi, Inception, Matchpoint, CobroVentures, GSK, Shenandoah (board member), Larkspur (board member) and Soltego (board member). The Gray laboratory receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. T.Z. is a scientific founder, equity holder and consultant of Matchpoint, equity holder of Shenandoah, and consultant of Lighthorse. M.R.G. reports research funding from Sanofi, Kite/Gilead, Abbvie and Allogene; consulting for Abbvie, Allogene and Bristol Myers Squibb; honoraria from Tessa Therapeutics, Monte Rosa Therapeutics and Daiichi Sankyo; and stock ownership of KDAc Therapeutics. Shenandoah has a license from Stanford for the TCIP technology that was invented by G.R.C., S.G., A.K., C-Y.C, W.W., S.H.K., N.S.G., W.J., X.L. and Z.L. All other authors declare no competing interests.
